17-ALLYLAMINO-17 DEMETHOXYGELDANAMYCIN (17-AAG) W/PACLITAXEL IN ADV SOLID TUMORS
17-ALLYLAMINO-17 DEMETHOXYGELDANAMYCIN (17-AAG) W/PACLITAXEL IN ADV SOLID TUMORS
批准号:
7378069
负责人:
Scot C Remick
金额:
$0.33万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-04-01 至 2007-03-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase I, multicenter study to evaluate the combination of weekly paclitaxel with 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) in patients with advanced solid malignancies. The hypothesis is that a weekly schedule of paclitaxel (administered for 3 out of 4 weeks) may be more suited to combine with 17-AAG from a pharmacodynamic standpoint, allowing for maximal exposure to both the agents. The objectives of this study are: 1) to determine the recommended doses for phase II studies of 17-AAG that can be administered in combination with weekly doses of paclitaxel in the above population; 2) to define the dose-limiting toxicities associated with this drug combination and to describe other non-dose-limiting toxicities; 3) to evaluate the pharmacokinetic interactions between the two drugs when given in combination; 4) to quantify changes in Hsp90 client proteins in peripheral blood mononuclear cells (PBMC) and to determine the extent and time-course of perturbations in microtubule architecture in PBMC and buccal mucosal cells upon treatment with this drug combination; 5) to compare concentrations of Hsp90 and its client proteins on tumor tissue pre- and post-treatment; 6) to document and describe the tumor responses of patients treated with the combination regimen. Treatment will be administered on an outpatient basis. Each treatment cycle consists of 28 days. Paclitaxel is administered on days 1,8, and 15 of each cycle, and 17-AAG will be administered on days 1,4, 8,11,15, and 18 of each cycle. Each agent will be administered as a 60-minute infusion. On days when both drugs are administered, the paclitaxel infusion will immediately follow the 17-AAG infusion. Dose escalation will proceed according to the details in the protocol. Blood samples for pharmacokinetic and pharmacodynamic studies will be drawn during Cycle 1 only. The estimated sample size for this study will be 25-35 subjects (6 subjects are expected at this site) over 3 years. The approximate accrual rate will be 3-4 patients/month. Six to 12 patients will be enrolled at the phase II recommended dose to obtain additional safety, pharmacokinetic and correlative science data. Subjects at this site will be seen at the GCRC on an outpatient basis during Cycle 1 only for administration of study agent, pharmacokinetics, and post biopsy care.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Period Seroprevalence (SARS-CoV-2) Survey in MHCCN Cancer Healthcare Workers (HCWs) Providing Patient Care during the Height of the Outbreak: A Registry Study
-
批准号:10166146
-
项目类别:
-
资助金额:$12.89万
-
财政年份:2019
-
负责人:Scot C Remick
-
依托单位:
Cancer and tobacco control training and research across the lifespan in Kenya
-
批准号:8337683
-
项目类别:
-
资助金额:$21.6万
-
财政年份:2012
-
负责人:Scot C Remick
-
依托单位:
Cancer and tobacco control training and research across the lifespan in Kenya
-
批准号:8531371
-
项目类别:
-
资助金额:$20.31万
-
财政年份:2012
-
负责人:Scot C Remick
-
依托单位:
Cancer and tobacco control training and research across the lifespan in Kenya
-
批准号:8652333
-
项目类别:
-
资助金额:$20.72万
-
财政年份:2012
-
负责人:Scot C Remick
-
依托单位:
Developing Research Capacity for AIDS Malignancy in Kenya
-
批准号:8125006
-
项目类别:
-
资助金额:$53.7万
-
财政年份:2010
-
负责人:Scot C Remick
-
依托单位:
Developing Research Capacity for AIDS Malignancy in Kenya
-
批准号:8698961
-
项目类别:
-
资助金额:$24.47万
-
财政年份:2010
-
负责人:Scot C Remick
-
依托单位:
Developing Research Capacity for AIDS Malignancy in Kenya
-
批准号:8308611
-
项目类别:
-
资助金额:$53.09万
-
财政年份:2010
-
负责人:Scot C Remick
-
依托单位:
Developing Research Capacity for AIDS Malignancy in Kenya
-
批准号:8009569
-
项目类别:
-
资助金额:$53.83万
-
财政年份:2010
-
负责人:Scot C Remick
-
依托单位:
PS-341 IN PATIENTS WITH ADVANCED MALIGNANCIES AND RENAL DYSFUNCTION
-
批准号:7378050
-
项目类别:
-
资助金额:$0.82万
-
财政年份:2006
-
负责人:Scot C Remick
-
依托单位:
COMBRETASTATIN/DOXORUBICIN/CISPLATIN FOR PATIENTS WITH THYROID CANCER
-
批准号:7378051
-
项目类别:
-
资助金额:$2.09万
-
财政年份:2006
-
负责人:Scot C Remick
-
依托单位:
COMBRETASTATIN A-4 PHOSPHATE IN ADVANCED ANAPLASTIC THYROID CARCINOMA
-
批准号:7378047
-
项目类别:
-
资助金额:$4.34万
-
财政年份:2006
-
负责人:Scot C Remick
-
依托单位:
EPOTHILONE B ANALOGUE BMS-247550 IN PTS WITH MALIGNANCIES & LIVER DYSFUNCTION
-
批准号:7378057
-
项目类别:
-
资助金额:$1.04万
-
财政年份:2006
-
负责人:Scot C Remick
-
依托单位:
17-DIMETHYLAMINOETHYLAMINO-17DEMETHOXYGELDANAMYCIN IN ADVANCED SOLID TUMORS
-
批准号:7378065
-
项目类别:
-
资助金额:$0.44万
-
财政年份:2006
-
负责人:Scot C Remick
-
依托单位:
BRYOSTATIN 1 + VINCRISTINE IN NON-HODGKIN'S LYMPHOMA POST TRANSPLANT
-
批准号:7378048
-
项目类别:
-
资助金额:$0.55万
-
财政年份:2006
-
负责人:Scot C Remick
-
依托单位:
SILICONE PHTHALOCYANINE 4 (PC4) PHOTODYNAMIC THERAPY FOR CUTANEOUS MALIGNANCIES
-
批准号:7202761
-
项目类别:
-
资助金额:$1.43万
-
财政年份:2005
-
负责人:Scot C Remick
-
依托单位:
EPOTHILONE B ANALOGUE BMS-247550 IN PTS WITH MALIGNANCIES AND LIVER DYSFUNCTION
-
批准号:7202789
-
项目类别:
-
资助金额:$1.22万
-
财政年份:2005
-
负责人:Scot C Remick
-
依托单位:
17-DIMETHYLAMINOETHYLAMINO-17DEMETHOXYGELDANAMYCIN IN ADVANCED SOLID TUMORS
-
批准号:7202797
-
项目类别:
-
资助金额:$3.02万
-
财政年份:2005
-
负责人:Scot C Remick
-
依托单位:
PS-341 IN PATIENTS WITH ADVANCED MALIGNANCIES AND RENAL DYSFUNCTION
-
批准号:7202778
-
项目类别:
-
资助金额:$2.75万
-
财政年份:2005
-
负责人:Scot C Remick
-
依托单位:
STI571 IN ADV MALIGNANCIES AMP; VARYING DEGREES OF RENAL DYSFUNCTION
-
批准号:7202762
-
项目类别:
-
资助金额:$0.74万
-
财政年份:2005
-
负责人:Scot C Remick
-
依托单位:
FENRETINIDE + PACLITAXEL + CISPLATIN FOR ADVANCED SOLID TUMORS
-
批准号:7202754
-
项目类别:
-
资助金额:$0.95万
-
财政年份:2005
-
负责人:Scot C Remick
-
依托单位:
海外基金